On October 8, 2026, Brink's Company announced that it has received acceptance in principle from the United Kingdom's Competition and Markets Authority (CMA) regarding its proposed remedy for the acquisition of NCR Atleos Corporation. This approval is contingent upon Brink's divesting its NoteMachine/TestLink UK operations to address regulatory concerns.

This development is significant for Brink's as it progresses towards closing the acquisition, which is anticipated to be finalized early in the first quarter of 2027. The merger is expected to enhance Brink's capabilities in cash and valuables management, bolstering its position within the freight and cargo transportation sector.

Background

Brink's Company, trading under the ticker BCO on the New York Stock Exchange, is a leading provider of cash and valuables management services. Incorporated in Virginia, the company operates globally, serving various clients including financial institutions and retailers. The company is classified under the SIC code 4731, which pertains to the arrangement of transportation of freight and cargo.

Recent filings indicate that Brink's has been actively working to finalize its acquisition of NCR Atleos, a move that could significantly reshape its service offerings and operational framework.

What the Filing Says

The filing states, "On October 8, 2026, The Brink's Company (the 'Company') issued a press release..." This press release details the CMA's acceptance of Brink's proposed remedy, which involves the divestiture of its NoteMachine/TestLink UK operations.

Impact

This update could impact various stakeholders, including Brink's shareholders, employees, and customers. The successful acquisition of NCR Atleos is expected to create synergies and enhance service offerings, potentially leading to improved customer solutions and operational efficiencies.

What's Next

The filing does not specify what happens next, but Brink's is committed to selecting a suitable buyer for NoteMachine/TestLink UK and concluding the divestiture process to avoid a CMA Phase 2 investigation.